SEC Tracker
Get the app

Enanta Pharmaceuticals ENTA

Enanta Pharmaceuticals names new COO as CEO retires

Item 5.02 Executive or director change, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. Dr. Jay Luly to retire as CEO on Feb 1, 2027
  2. Dr. Tara Kieffer appointed COO, joined Enanta in 2020
  3. Board starts search for CEO successor
  4. Dr. Luly to serve as strategic advisor in 2027

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Enanta Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. TuHURA Biosciences HURA public float $111M, Jun 30, 2025
  2. Galectin Therapeutics GALT public float $109M, Jun 30, 2025
  3. Protara Therapeutics PRTO public float $112M, Jun 30, 2025
  4. Cartesian Therapeutics RNAC public float $109M, Jun 30, 2025
  5. Caribou Biosciences CRBU public float $113M, Jun 30, 2025